In biotech and pharma, an influencer is a physician, a scientist, or a patient advocate – not someone with a ring light. We build KOL and disease-community influencer programs that generate real reach without triggering an off-label promotion problem or a missed Sunshine Act filing.
The Problem
Promotional and medical affairs engagement get mixed together
Marketing books a KOL for a paid, branded video, then the same physician does an unpaid educational webinar for medical affairs the following month. Nobody has drawn the line between the two. Once commercial and scientific engagement blur, every piece of content that physician touches becomes a promotional liability, including the ones medical affairs never intended to be promotional.
No system for tracking payments to physician influencers
A KOL gets a speaking fee, a content fee, and travel reimbursement from three different budget lines, and none of it gets reconciled against Open Payments reporting requirements. By the time compliance asks for the Sunshine Act submission, marketing is reconstructing spend from old invoices and Slack threads instead of a system built to capture it as it happens.
MLR is a bottleneck because it was never built into the content plan
Content gets scripted, shot, and edited before anyone loops in Medical-Legal-Review. Then it sits for three weeks while legal flags a claim the KOL made off-script, and the launch window closes. Teams either miss the window or skip the review, and neither outcome is acceptable.
Patient advocacy relationships are run as PR, not as a program
A patient advocacy group leader gets a one-off co-branded post around a conference, then nothing for eight months. There is no ongoing relationship, no disclosure standard for compensation, and no plan for what happens if that leader starts discussing off-label use of the product in their own channels.
How We Help
We start with an audit, not a content calendar. We map every physician, scientist, and patient advocate your company currently pays, mentions, or partners with, and we sort each relationship into one of two buckets: promotional (marketing-owned, subject to FDA disclosure and MLR) or scientific/educational (medical affairs-owned, governed by different rules on interaction and compensation). Most companies we work with have never done this sort. Once it exists, every downstream decision gets easier.
From there we build the compliance infrastructure before we build the content. That means a payment-tracking process tied to your finance system so Sunshine Act reporting is a byproduct of normal operations, not a quarterly scramble. It means an MLR submission calendar built around your actual review cycle time, so content is scripted with claims that will clear review the first time, not the third. It means a disclosure standard for KOLs and patient advocates that matches what FDA and FTC actually require, not a generic influencer contract pulled from a consumer template.
With the infrastructure in place, we identify and vet the actual influencers: physician KOLs with genuine standing in your therapeutic area, disease-community patient influencers with real audiences (not just follower counts), and patient advocacy group leaders whose organizations align with your indication. We check each one against existing pharma company relationships, prior off-label statements, and conflict-of-interest exposure before a single contract gets signed.
Execution follows a strict lane discipline. Promotional content runs through marketing with full MLR review and Sunshine Act tagging. Medical affairs content – peer-to-peer education, scientific exchange, advisory board output – runs through a separate approval path with its own documentation trail. We never let a KOL's promotional appearance get repurposed as "educational" content to skip review, and we never let scientific exchange get dressed up as marketing to hit a launch date.
Measurement is built around what actually matters for a regulated product: content that cleared review on schedule, disclosure compliance rate, physician and patient reach in the specific disease community (not vanity reach), and downstream engagement like HCP portal visits or patient support enrollment. We report against those, not generic impression counts.
What makes this different from a generic influencer agency is that we are not translating consumer influencer tactics into pharma. We build the program around FDA promotional review requirements, Sunshine Act obligations, and the promotional/medical affairs split from the first assessment, so the influencer program does not become the reason your next warning letter gets written.
What we deliver
- KOL and patient influencer audit with promotional vs. medical affairs classification
- Sunshine Act payment-tracking workflow tied to your finance and legal teams
- MLR submission calendar and claims playbook built around your actual review cycle
- KOL and patient advocate vetting, including conflict and prior-statement screening
- Disclosure standards and contract templates for physician and patient influencer content
- Patient advocacy partnership strategy tied to specific disease states, not one-off events
- Content production support for both promotional and medical affairs channels
- Quarterly reporting on disclosure compliance, review timelines, and community engagement
If a KOL's content promotes the drug, it needs an MLR sign-off and a Sunshine Act entry – calling it 'educational' after the fact does not change which bucket it belongs in.
Our Methodology
We run this as a 90-day sprint because the compliance foundation has to exist before a single piece of KOL content ships. Days 1-30 are the audit: every current physician, scientist, and patient advocate relationship gets mapped, classified as promotional or medical affairs, and checked against existing payment and disclosure records. This is where most of the risk in an existing program surfaces.
Days 30-60 build the infrastructure: the Sunshine Act tracking workflow, the MLR calendar, the disclosure contract language, and the vetting criteria for any new KOL or patient advocate. We also identify the first wave of influencer partners and begin the vetting process in parallel, so execution is not waiting on infrastructure to finish.
Days 60-90 are launch and measurement. The first promotional and medical affairs content runs through their respective review paths, disclosure and payment data start flowing into the tracking system automatically, and we set the reporting cadence your legal and marketing teams will use going forward. By day 90 you have a running program with a compliance trail, not a pile of unreviewed content and a spreadsheet of untracked payments.
How We Work
The first 30 days are diagnostic. We interview marketing, medical affairs, and legal separately, because they usually describe the current KOL program differently, and the gaps between those descriptions are where the risk lives. You get a written classification of every existing relationship and a prioritized list of what needs to be fixed before any new content goes out.
Days 30-60 are build days. We work directly with your legal and compliance teams on the Sunshine Act and MLR workflows rather than handing over a generic template, because your review cycle time, your finance system, and your existing contract language all shape what will actually get used. In parallel we start vetting the first round of KOLs and patient advocates.
Days 60-90 are execution and handoff. We run the first promotional and medical affairs content through the new process end to end, and we make sure your internal team can run the next cycle without us in the room. Cadence during the engagement is a weekly working session plus a standing legal/compliance touchpoint, since sign-off from those two functions is what determines whether the program actually ships on schedule.
Our team is small and senior: a lead who has run pharma marketing operations, someone who owns the compliance and disclosure build, and a content producer who understands MLR constraints going into the script, not after. If your biotech or pharma company needs an influencer program that a compliance audit will not unwind, we should talk.
- Clear, documented separation between promotional and medical affairs KOL engagement
- Sunshine Act payment data captured as part of normal workflow, not reconstructed after the fact
- Shorter time from content draft to MLR sign-off
- Fewer content pieces rejected or pulled after publication for claims issues
- Ongoing patient advocacy partnerships tied to specific disease states instead of one-off appearances
- A vetted bench of physician and patient influencers ready for future launches
If your biotech & pharma company needs influencer marketing leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
What is the difference between promotional and medical affairs KOL engagement?
Promotional engagement is marketing-driven and aimed at supporting the commercial message for an approved indication; it requires MLR review and Sunshine Act disclosure. Medical affairs engagement is scientific exchange – advisory boards, peer-to-peer education, unbranded disease-state discussion – and follows a separate compliance path with different rules on interaction. The two get confused most often when the same physician does both types of work for the same company, and nobody has documented which hat they are wearing on a given project.
Do payments to physician influencers need to be reported under the Sunshine Act?
Yes, if the physician is a covered recipient and the payment is a transfer of value from a manufacturer, it falls under Open Payments reporting regardless of whether the engagement is called marketing or influencer work. That includes content fees, speaking fees, travel, and in some cases free product or services. We build a tracking workflow so these payments are captured at the time they occur instead of reconstructed at reporting deadline.
How does Medical-Legal-Review fit into KOL content production?
MLR should review every promotional claim a KOL makes on your behalf before it publishes, including anything said on camera, in a script, or in a social post you paid for or coordinated. The fix is building the review step into the production calendar from the start, with claims pre-checked against label language, rather than shooting first and hoping the content clears review unedited.
Can patient advocacy leaders be compensated for content or partnerships?
Yes, but the compensation and the relationship need clear disclosure, and the content needs the same claims discipline as any promotional material if it touches your product directly. We build patient advocacy partnerships around ongoing disease-state engagement with documented compensation terms, rather than one-off paid posts that create disclosure ambiguity.
What is the risk of off-label promotion through influencer content?
If a KOL or patient influencer discusses uses, populations, or outcomes outside your approved label in content you paid for, coordinated, or amplified, that can be treated as off-label promotion regardless of intent. The risk is highest when influencer content is unscripted or when a physician's independent commentary gets reposted or boosted by the company. We screen for this in vetting and build review checkpoints into any content the company touches.
How long does it take to launch a compliant KOL program?
Our engagement runs 90 days: 30 days to audit existing relationships and classify them, 30 days to build the Sunshine Act and MLR workflows, and 30 days to launch the first content and start regular reporting. Companies with no existing compliance infrastructure sometimes need more time on the build phase, but the audit and classification always happen first.
